Combination therapy in COVID 19
Phase 2
Recruiting
- Conditions
- COVID-19 pneumonia.
- Registration Number
- IRCT20100228003449N30
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Patients with highly suspected or confirmed COVID-19 who are candid for hospitalization and starting triple-drug combination
Exclusion Criteria
History of drug allergy
Pregnancy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical response. Timepoint: Every other day. Method of measurement: Evaluation of clinical signs and symptoms.;Paraclinical response. Timepoint: Every other day. Method of measurement: Laboratory and radiological findings.;Adverse drug reactions. Timepoint: Every other day. Method of measurement: Interview and laboratory data.
- Secondary Outcome Measures
Name Time Method Duration of hospitalization. Timepoint: End of hospitalization. Method of measurement: Medical records.;Clinical outcome. Timepoint: End of study. Method of measurement: Patient's record.